Once-daily single pill simplifies HIV cocktail

Article

With the Food & Drug Administration's approval of Atripla (efavirenz/emtricitabine/tenofovir, Bristol-Myers Squibb and Gilead Sciences), HIV patients will have access to a once-daily single-tablet regimen. The new product combines three agents from two classes of antiretrovirals: Efavirenz (600 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI); and emtricitabine (200 mg) and tenofovir (300 mg) are nucleoside reverse transcriptase inhibitors (NRTIs). All three work by blocking reverse transcriptase, an enzyme required for HIV replication.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.